GeoVax Labs, Inc. (NasdaqCM: GOVX)
Health Care · Biotechnology · US
$0.64
-0.62% today · -96.6% 1Y
GeoVax Labs, Inc. (NasdaqCM: GOVX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.76M and employs 19 people.
Over the last twelve months the share price has lost 96.6%, trading between 0.59 and 20.00.
Tweenvest scores GeoVax Labs, Inc. across four factors: quality 26/100. Its strongest factor is quality.
GOVX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.76M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -8.75
- Dividend yield
- —
- Beta (5Y)
- 3.66
- 52-week high
- $20.00
- 52-week low
- $0.59
- Avg volume (3M)
- —
- Shares outstanding
- 7.37M
- Employees
- 19
- Next earnings
- —
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
- ISIN
- US3736787058
- Founded
- 1988
- Listed since
- Sep 25, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.